



10 February 2021

Company Announcements Office
ASX Limited

Dear Sir/Madam

Actinogen Medical Limited
Cleansing Notice under section 708A of the Corporations Act 2001 (Cth)

On 15 October 2020, **Actinogen Medical Limited** ACN 086 778 476 (ASX:ACW) (**Actinogen** or the **Company**) announced a non-renounceable rights issue, which closed on 10 November 2020. The Company pursuant to ASX Listing Rule 7.2 Exception 3 has now issued 161,409,078 shares pursuant to the rights issue shortfall to various sophisticated and institutional investors (**Shortfall Placement**).

Actinogen gives this cleansing notice (**Notice**) under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**). The Shortfall Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act on 10 February 2021.

As at the date of this Notice, the Company has complied with:

- the provisions of Chapter 2M of the Corporations Act as they apply to Actinogen; and
- section 674 of the Corporations Act.

As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

Yours faithfully

A handwritten signature in black ink, appearing to read "Peter Webse", is written over a light blue horizontal line.

Peter Webse
Company Secretary

Actinogen Medical
Dr Geoff Brooke
Executive Chairman
P: +61 2 8964 7401
E: geoff.brooke@actinogen.com.au

Investor Enquiries
Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Authorised by the Board of Directors of Actinogen Medical